Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Clinical and Translational Gastroenterology

Volumn 7, Issue , 2016, Pages

  Roda, Giulia ^a   Jharap, Bindia ^b   Neeraj, Narula ^a   Colombel, Jean Frederic ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB;

ANTIBODY PRODUCTION; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INCIDENCE; INDUCTION CHEMOTHERAPY; INFLAMMATORY BOWEL DISEASE; LOSS OF RESPONSE; PRIMARY NONRESPONSE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REMISSION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84953887794     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.63     Document Type: Review

References (56)

1. Sherman M, Tsynman DN, Kim A et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014; 15: 174-179.
2. Sprakes MB, Ford AC, Warren L et al.. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012; 6: 143-153.
3. Hanauer SB, Feagan BG, Lichtenstein GR et al. ACCENT I Study group. Maintanance Infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 59: 1541-1549.
4. Sands B, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885.
5. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659.
6. Ben-Hori S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24-30.
7. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-948.
8. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-366.
9. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627.
10. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
11. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.
12. Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147: 1296-1307.
13. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
14. Fausel R, Afzali A. Biologics in the management of ulcerative colitis-comparative safety and efficacy of TNF- antagonists. Ther Clin Risk Manag 2015; 11: 63-73.
15. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767.
16. D'Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response Am J Gastroenterol 2011; 106: 199-212.
17. Ben-Horin S, Chowers Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-995.
18. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease. A systematic review. Am J Gastroenterol 2011; 106: 674-684.
19. Ben-Horin S. Loss of response to anti-tumor necrosis factors: What is the next step Dig Dis 2014; 32: 384-388.
20. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: The CHARM trial. Gastroenterology 2007; 132: 52-65.
21. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistula s in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
22. Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Annals of gastroenterology 2014; 27: 304-312.
23. Katz L, Taylor RP, Cunningham MR et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026-2033.
24. Rojas JT, Taylor RP, Cunningham MR et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolugus monkeys. J Pharmacol Exp Ther 2005;313:578-585.
25. Paul S, Moreau AC, Del Tedesco E et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1288-1295.
26. Roblin X, Marotte H, Rinaudo M et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-84.
27. Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40: 620-628.
28. West RL, Zelinkova Z, Wolbink GJ et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-1126.
29. Billioud V, Laharie D, Filippi J et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011; 17: 152-159.
30. Lopez A, Billioud V, Peyrin-Biroulet C et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013; 19: 1528-1533.
31. Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human antichimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-1139.
32. Yanai H, Lichtenstein L, Assa A et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015; 13: 522-530.
33. Roblin X, Rinaudo M, Del Tedesco E et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1250-1256.
34. Ben-Horin S, Yavzori M, Katz L et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-48.
35. St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459.
36. Cesarini M, Katsanos K, Papamichael K et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014; 46: 135-139.
37. Alten R, van den Bosc F. Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis 2014; 17: 5-18.
38. Casteele N, Gils A, Singh S et al. Antibody Response to Infliximab and its impact on Pharmacokinetics can be transient. Am J of Gastroenterol 2013; 108: 962-971.
39. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239.
40. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
41. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553.
42. Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444.
43. Ong DE, Kamm MA, Hartono JL et al. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. Gastroenterol Hepatol 2013; 28: 1595-1599.
44. Yarur A, Kubiliun M, Czul F et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118-1124.
45. Cornillie F, Hanauer SB, Diamond RH et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-1727.
46. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868.
47. Sokol H, Seksik P, Carrat F et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-1368.
48. Jones GR, Kennedy NA, Lees CW et al. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance-progress and prospects. Aliment Pharmacol Ther 2014; 39: 1253-1265.
49. Colombel JF, Feagan BG, Sandborn WJ et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-358.
50. Vande Casteele N, Ann Gils. Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of crohn's disease: avoiding failure while lowering costs Dig Dis Sci 2015; 60: 2571-2573.
51. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924.
52. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610.
53. Haridas V, Darnay BG, Natarajan K et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 1998; 160: 3152-3162.
54. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
55. Grell M, Zimmermann G, Gottfried E et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membraneanchored TNF. EMBO J 1999; 18: 3034-3043.
56. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.